National Center for Advancing Translational Sciences (NCATS), NIH, Office of Strategic Alliances, 9800 Medical Center Drive, Building B, Room B3005, Bethesda, MD 20892-3370, USA.
Curr Top Med Chem. 2014;14(3):326-9. doi: 10.2174/1568026613666131127155703.
The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.
美国国立卫生研究院(NIH)、学术医学中心和工业界在合作方面有着悠久而富有成效的历史。私营和公共部门研发预算的减少,使得这种合作变得至关重要,以降低进一步减少创新药物数量的风险,从而满足紧迫的公共卫生需求。在资源有限的情况下,无论是工业界还是公共部门研究机构(PSRIs)都被迫利用资源和专业知识来降低项目风险。此外,这也为设想和实施新方法以实现这些目标提供了机会。我们讨论了 NIH 中的几个这样的创新合作和伙伴关系,展示了 NIH 和工业界如何共同努力加强药物开发管道。